Cell proliferation inhibition and antitumor activity of novel alkyl series of diorganotin(IV) compounds
- 31 July 2007
- journal article
- research article
- Published by Wiley in Journal of Applied Toxicology
- Vol. 28 (4) , 430-438
Abstract
Diorganotin(IV) compounds, R2SnCl2 are often tetrahedral, and structurally resemble the active platinum compounds, i.e. cisplatin, and consequently a large number of such complexes have been tested for antitumor activity. A structural correlation with biological activity for diorganotin(IV) complexes has shown that active species are associated with complexes having Sn–N bonds longer than 2.39 Å which in turn determines the formation of a tin–DNA complex. In view of these, a series of diorganotin(IV) dichloride complexes of N‐(2‐pyridylmethylene)arylamine (nitrogen‐chelating ligands) has been synthesized and characterized on the basis of IR, NMR and 119Sn‐Mössbauer studies. In the present study, an attempt was made to determine the comparative antiproliferative and antitumor effect of diorganotin(IV) complexes with different alkyl groups [Me2SnCl2·L1 (OTC‐1), Et2SnCl2·L2 (OTC‐2) and nBu2SnCl2·L2 (OTC‐3)]. The present study in human lymphocytes demonstrated that these diorganotin(IV) complexes could block the cell cycle progression and induce sister chromatid exchanges (SCEs) significantly, however, with respect to the induction of chromosome aberrations (CAs) it was very mild. Both the levels of p53 and p16 proteins were raised after diorganotin(IV) treatment and such induction was maximum in the OTC‐3 treated samples. The antitumor activity was determined in accordance with the US National Cancer Institute (NCI) standard protocol for primary screening in Dalton's lymphoma that was maintained by serial intraperitoneal transplantation. The T/C (treated/control) value was increased (186% with OTC‐3) when diorganotin(IV) was given after transplantation. The data suggest that the OTC‐3 has better antiproliferative and antitumor activity and endogenous glutathione level has no influence on the effect of OTC‐3. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- 50 Sn Tin Compounds and Their Therapeutic Potential2005
- Resveratrol analog (Z)‐3,5,4′‐trimethoxystilbene is a potent anti‐mitotic drug inhibiting tubulin polymerizationInternational Journal of Cancer, 2003
- Caspase Involvement in the Induction of Apoptosis by the Environmental Toxicants Tributyltin and TriphenyltinToxicology and Applied Pharmacology, 1999
- Synthesis and characterization of diorganotin(IV) complexes ofN-(2-pyridylmethylene)arylamines and mutagenicity testingin vivo of Et2SnCl2 [L4=N-(2-pyridylmethylene)-4-toluidine]Applied Organometallic Chemistry, 1998
- Organotin-Induced Apoptosis as ObservedIs Not Relevant for Induction of Thymus Atrophy at Antiproliferative DosesToxicology and Applied Pharmacology, 1997
- Molecular biology of the cell cycle: Potential for therapeutic applications in radiation oncologySeminars in Radiation Oncology, 1996
- The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinasesCell, 1993
- Inhibition of mouse spleen cell activity by organotin compounds: Effect of attachment of a maltose residue to the organotin groupInternational Journal of Immunopharmacology, 1993
- Crystal and molecular structure and in vitro antiproliferative and antitumor activity of two organotin(IV) carbohydrate compoundsJournal of Medicinal Chemistry, 1993
- Possible pre-dissociation of diorganotin dihalide complexes: Relationship between antitumour activity and structureCancer Letters, 1984